As we demonstrated that loss of moesin is correlated with increased HER2 expression in multiple cancers, the use of the moesin‐mimicking compound to inhibit HER2 such as ebselen oxide could represent a personalized therapeutic option for HER2+ cancer patients displaying a low intratumoral level of moesin. This evidence concerns the gene ERBB2 and cancer.